Sialic acids are terminal acidic monosaccharides, which influence the chemical and biological features of glycoconjugates. Their removal catalyzed by a sialidase modulates various biological processes through change in conformation and creation or loss of binding sites of functional molecules. Sialidases exist widely in vertebrates and also in a variety of microorganisms. Recent research on mammalian sialidases has provided evidence for great importance of these enzymes in various cellular functions, including lysosomal catabolism, whereas microbial sialidases appear to play roles limited to nutrition and pathogenesis. Four types of mammalian sialidases have been identified and characterized to date, designated as NEU1, NEU2, NEU3 and NEU4. They are encoded by different genes and differ in major subcellular localization and enzymatic properties including substrate specificity, and each has been found to play a unique role depending on its particular properties. This review is an attempt to concisely summarize current knowledge concerning mammalian sialidases, with an especial focus on their properties and physiological and pathological roles in cellular functions.
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General properties of mammalian sialidases
Sialidases (EC 3.2.1.18, also called neuraminidases) are glycosidases catalyzing the removal of α-glycosidically linked sialic acid residues from carbohydrate groups of glycoproteins and glycolipids. They are widely distributed in vertebrates and also in microorganisms including viruses, bacteria, fungi, mycoplasma and protozoa (Rosenberg and Schengrund 1976; Corfield et al. 1981; Corfield and Schauer 1982; Corfield 1992; Saito and Yu 1995) . Sialidase activity in higher organisms was detected for the first time in commercial preparations of bovine and human glycoproteins in Cohn Fraction VI (Warren and Spearing 1960) and numerous papers since then have demonstrated its presence in a wide variety of mammalian cells and tissues. Carubelli et al. (1962) detected activity in soluble fractions isolated from different tissues of rats, and several reports described a lysosomal occurrence (Mahadevan et al. 1967 ). Subsequently, it was detected in plasma membranes (Schengrund and Rosenberg 1970) and Golgi fractions (Kishore et al. 1975) . However, in the early days, it remained uncertain whether the activities originated from the same or different types of sialidase, partly because of molecular instability and low levels of expression.
Subsequently, biochemical isolation and characterization of sialidases from rat tissues provided evidence for the existence of four types of sialidases differing in their subcellular localization and enzymatic properties (Miyagi and Tsuiki 1984, 1985; Miyagi et al. 1990 ). Molecular cloning of sialidases has validated these four forms and facilitated elucidation of their functional roles. General properties of the four mammalian sialidases are compared in Table I . NEU1, NEU2 and NEU3 are now known to be localized predominantly in the lysosomes, cytosol and plasma membranes, respectively, and NEU4 is found in lysosomes or in mitochondria and endoplastic reticulum. However, recent observations have revealed that the subcellular localization can vary with particular cell stimuli. NEU1 is a well-known case and NEU4 also demonstrates mobilization to the cell surface under certain conditions, although the molecular mechanisms are not fully understood. Consistent with previous observations on sialidase activity in nuclear membranes (Saito et al. 1996) , a recent report suggested the presence of NEU1 in the outer and NEU3 in the inner membrane of the nuclear envelope (Wang, Wu et al. 2009 ). Furthermore, NEU2 has been detected not only in cytosol, but also in the nucleoplasm of rat muscle fibers, as assessed by immunohistochemical electron microscopy, probably due to the presence of a nuclear localization signal near the N-terminus (Akita et al. 1997) .
Genomic organization of the sialidase genes is illustrated in Figure 1A . In the primary sequences, all contain several Asp boxes (-Ser-X-Asp-X-Gly-X-Thr-Trp-; Roggentin et al. 1993) and the RIP (-Phe (Tyr)-Arg-Ileu-Pro-) sequence, conserved sequences found in topologically equivalent positions in all forms, despite the mammalian enzymes not exhibiting any other particular similarity to microbial sialidases. Multiple amino acid sequence alignment of the four types of mammalian sialidases and the Salmonella typhimurium enzyme has revealed a similarity in spatial arrangement of the conserved amino acid residues as shown in Figure 2 . Distinctive behavioral differences in response to inhibitors between mammalian and microbial sialidases are suggestive of molecular variation. For example, anti-influenza drugs, Tamiflu (oseltamivir) and Relenza (zanamivir) , are known to be clinically effective at 1.2 and 0.05-0.43 μM, respectively, following administration in the plasma of patients. However, in vitro, Tamiflu was found to hardly affect any of the human sialidases, even at 1 mM, and Relenza significantly inhibited NEU3 and NEU2 only in the micromolar range (Ki 3.7 ± 0.48 and 12.9 ± 0.07 μM, respectively), contrasting with the low nanomolar concentrations at which blocks the activity of viral sialidases Chavas et al. 2010) . A sialic acid analog 2-deoxy-2,3dehydro-N-acetylneuraminic acid (DANA), Neu5Ac2en, is known to be a common inhibitor of almost all members of sialidases, but viral and bacterial sialidases are 10 times more sensitive than their mammalian counterparts. Detailed structural information has been provided by the determination of three-dimensional structure for human NEU2 by X-ray crystallography (Chavas et al. 2005) . The enzyme possesses the canonical six-blade β-propeller, observed in viral and bacterial sialidases, with its active site in a shallow crevice. In NEU2 and DANA complexes, the inhibitor lies in the catalytic crevice surrounded by 10 amino acids, including the arginine triad and the tyrosine residue Tyr334, conserved in mammalian, bacterial and viral sialidases. However, the N-acetyl and glycerol moieties of DANA interact with the NEU2 amino acid residues in a manner different from those of bacterial and viral sialidases, this being regarded as a key structural difference for the design of drugs applicable against infectious microbes.
Among human sialidases, the overall amino acid identity of NEU1 to the other sialidases is relatively low (19-24%), whereas NEU2, NEU3 and NEU4 show 34-40% homology to each other. The four sialidases possess different substrate specificities as shown in Table I . In particular, NEU1 hardly hydrolyzes gangliosides and NEU3 acts preferentially on gangliosides but not glycoproteins. It is a characteristic feature of NEU4 that it acts on mucin (Seyrantepe et al. 2004; Yamaguchi et al. 2005) . With regard to the glycosidic linkage specificity, oligosaccharide substrates possessing the α2-3 sialyl linkage are hydrolyzed faster than those with α2-6 and α2-8 linkages by NEU1 (Miyagi and Tsuiki 1984) and NEU2 (Miyagi and Tsuiki 1985) , whereas NEU3 hydrolyzes gangliosides with α2-3 (GM3) and α2-8 (GD3) linkages almost equally and faster than those with α2-6 linkage (synthetic GM3). GM3 containing N-glycolylneuraminic acid is hydrolyzed by NEU3 at a lower rate [46% of that containing N-acetylneuraminic acid (NeuAc); Hata et al. 1998 ]. O-Acetylated sialic acids block sialidase action of all the mammalian enzymes (Corfield and Schauer 1982) . Because of low expression of mammalian sialidases when compared with general proteins, it is not easy to detect endogenous sialidase in tissue sections, but sensitive fluorescent imaging for the activity is possible using 5-bromo-4-chloroindol-3-yl-a-D-N-acetylneuraminic acid and an azo dye Fast Red Violet LB (Minami et al. 2011 ). The drawback is the uncertainty regarding the type of sialidases involved.
Although many functional aspects are not fully understood, recent progress in gene cloning has facilitated elucidation of important biological roles in cellular functions including cell differentiation, cell growth and apoptosis. Regarding the comparative endogenous level, each sialidase is expressed in a tissue-and a species-specific manner. In human tissues, NEU1 generally shows the strongest expression, 10-20 times greater than those of NEU3 and NEU4, whereas NEU2 expression is extremely low at the most at only 4000 to 10,000th of the NEU1 value in a range of tissues , as assessed by a quantitative real-time RT-PCR using a standard curve for each cDNA. In rat and mouse tissues, different situations prevail. Herein, we focus on cellular For the subcellular localization of human NEU4, two different descriptions have been reported on the basis of gene transfection studies. b Human NEU4 consists of two forms, long (L) and short (S) forms, which differ in the presence of 12 N-terminal amino acid residues, and mouse NEU4 also presents as two isoforms, designated NEU4a and NEU4b with and without 23 amino acid stretch at N-terminus, respectively.
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functions of mammalian sialidases, extending the earlier literature on recent studies of mammalian sialidase (Achyuthan and Achyuthan 2001; Monti et al. 2002 Monti et al. , 2010 Miyagi and Yamaguchi 2007; Miyagi 2008) .
Sialidase NEU1
The human NEU1 gene was identified as a major histocompatibility complex (MHC)-related sialidase gene by searching the database for an expressed sequence tag, having predicted amino acid sequences with homology to a mammalian cytosolic sialidase and a bacterial sialidase, including the F(Y)RIP sequence and Asp boxes (Bonten et al. 1996; Pshezhetsky et al. 1997) . The same gene was also identified by chromosome mapping of region responsible for sialidase deficiency . Taking advantage of an SM/J mouse strain carrying a defective sialidase allele, the mouse Neu1 gene was identified Igdoura et al. 1998; Rottier et al. 1998 ) and mapped to chromosome 17, in a (Monti et al. 1999 ) and no information is available for untranslated region(s) of the gene at present. The structure of NEU3 gene is based on recent results . (B) Schematic representations of human (a) and mouse (b) NEU4 proteins. Transcripts with different 5′ exons encode the two forms, which are generated by alternative splicing. Human NEU4 consists of two forms, long (L) and short (S) forms, which differ in the presence of 12 N-terminal amino acid residues, possibly acting as mitochondrial targeting (gray box; Yamaguchi et al. 2005) . For the human NEU4, NM_080741.2 and NM_001167599.1 are capable of encoding the long form, whereas NM_001167600.1, NM_001167601.1 and NM_001167602.1 generate the short form. Mouse NEU4 also presents as two isoforms, designated NEU4a and NEU4b. Neu4a has an additional 23 amino acid stretch at N-terminus (Shiozaki, Koseki et al. 2009 ).
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region which is syntenic to human MHC on chromosome 6. The human NEU1 gene comprises 6 exons encompassing over 5 kb ( Figure 1A ) and maps to 6p21.3. Northern blotting analysis revealed an 1.9-kb transcript detected ubiquitously in human tissues (Bonten et al. 1996) . Although the promoter region of the mouse Neu1 gene has been assigned and homologous regions are found upstream of the human NEU1 and rat Neu1 genes (Champigny et al. 2003) , the molecular Fig. 2 . Sequence alignment of human and S. typhimurium sialidases. The sequences were aligned by using the PAPIA ( parallel protein information analysis) program and minor adjustments were made by the eye. Conserved F(Y)RIP sequence motifs are underlined and conserved Asp boxes are indicated by boxes. The amino acid residues of the active site assigned by the crystallographic analysis of human NEU2 (Chavas et al. 2005 ) and S. typhimurium (Crennell et al. 1993) sialidase are indicated by open circles and asterisks, respectively. (Reprinted from page 308 in Miyagi and Yamaguchi, 2007 with permission from Elsevier).
Cellular functions of mammalian sialidases mechanisms responsible for transcriptional control of these genes largely remain to be elucidated. Human lysosomal sialidase NEU1 is associated with a carboxypeptidase protective protein/cathepsin A (PPCA) and a β-galactosidase as a complex in lysosomes, dissociation leading to sialidase inactivation (D'Azzo et al. 1982; Galjart et al. 1988 ). The human NEU1 features a lysosomal C-terminal targeting motif and evidence has been generated that the protective protein is responsible for transport lysosomal compartmentalization, also playing important roles in maturation as well as activation of NEU1 through heterodimer formation ). The N-terminal N-glycans of NEU1 are important for maintaining stability or catalytic activity, and the PPCA can compensate for N-glycan defects (Wang, Zaitsev et al. 2009 ). In addition, recent observations revealed the subcellular localization of NEU1 sialidase in plasma membrane as well as within lysosomes under conditions of cell stimulation (Lukong et al. 2001; Cross et al. 2003; Liang et al. 2006) , which seems to be connected to novel physiological functions. Homology modeling of mammalian sialidase based on NEU2 allowed prediction that the active site crevice of NEU1 is different from those of NEU2, NEU3 and NEU4, in agreement with low homology to the other three sialidases in terms of their primary sequences. The predicted difference was used to design selective inhibitors for each of the sialidases, and compounds showing selectivity toward NEU1 with IC 50 values 10 times lower than for DANA itself were identified in a series of amide-linked C9 modified DANA forms (Magesh et al. 2008) .
NEU1 is linked to two neurodegenerative lysosomal storage disorders: sialidosis and galactosialidosis. The former is caused by defects in the genomic DNA, including frameshift insertions and missense mutations, and the latter features a combined deficiency of NEU1 and β-galactosidase due to the absence of a functional PPCA, leading to defective or deficient enzyme activity. Transfection of NEU1 cDNA restored normal levels of sialidase activity toward a synthetic substrate, 4MU-NeuAc, in human sialidosis fibroblasts, indicating that it is a target gene for sialidosis (Bonten et al. 1996; Pshezhetsky et al. 1997) . The sialidase possesses narrow substrate specificity, with oligosaccharides and glycopeptides serving as good substrates, sialyloligosaccharides becoming increased in sialidosis patients' urine and fibroblasts. Pathology of NEU1 gene in sialidosis has been well outlined in the literature (Seyrantepe et al. 2003; d'Azzo and Bonten 2010) .
Interestingly, NEU1 negatively regulates lysosomal exocytosis, a cellular process for the recruitment of lysosomes to the plasma membrane, resulting in an increase in extracellular proteolytic activity (Yogalingam et al. 2008) . In Neu1(−/−) mice, hypersialylated lysosomal-associated membrane protein 1 (LAMP-1) accumulates at the cell surfaces of hematopoietic cells, indicating fusion of lysosomes with the plasma membrane. In contrast, silencing of LAMP-1 expression in the cells leads to normalization of the abnormal LAMP-1 distribution and reduction in lysosomal exocytosis, LAMP-1 being identified as a target substrate of NEU1. Increased lysosomal exocytosis actually leads to pathological manifestations in Neu1(−/−) mice, with hearing loss (Wu et al. 2010 ) and muscle degeneration (Zanoteli et al. 2010) observed as sialidosis phenotypes. Marked increase in the expression and apical localization of LAMP-1 in marginal cells of the stria vascularis causes the dysfunction of transduction in sensory hair cells, and the infiltration of muscle fibers by expanded connective tissues brings about muscle degeneration.
In addition to glycoconjugate catabolism in lysosomes, NEU1 is involved in cellular signaling for immune responses and elastic fiber assembly through transportation to plasma membranes (reviewed in Pshezhetsky and Hinek 2011) . Sialidase activity in activated T lymphocytes contributes to hyposialylation of specific cell surface glycoconjugates and to production of Interferon gamma (IFNγ) (Nan et al. 2007 ). In human T-cells, both NEU1 and NEU3 mRNAs are significantly induced by T-cell receptor stimulation, and several cytokines, including interleukin (IL)-2 and IL-13, are induced upon the up-regulation of these sialidases (Stamatos et al. 2005) , with probable important immunoregulatory roles. During PMA ( phorbol 12-myristate 13-acetate)-induced monocyte differentiation, NEU1 is up-regulated and targeted together with PPCA to MHCII-positive vesicles that merge later with the plasma membrane (Liang et al. 2006) . In line with these findings, there is the evidence that NEU1 contributes to the regulation of phagocytosis in macrophages and dendritic cells through the desialylation of surface receptors using the cells from mouse models of a PPCA deficiency and a double PPCA/Neu1deficiency (Seyrantepe, Iannello et al. 2010) . Cell surface NEU1 activates phagocytosis in immune cells probably by affecting sialylation and phosphorylation of multiple receptors for phagocytosis, including Fc receptors for immunoglobulin G. Desialylation of sialyl α-2,3-linked β-galactosyl residues of Toll-like receptor 4 (TLR4) by NEU1 may be essential for receptor activation and cellular signaling via NFkB activation in dendritic and macrophage cells . It has further been suggested that activation of the ligand-induced TLR4 and subsequent signaling may be brought about by binding of complexes of NEU1 and matrix metalloprotease-9 to TLR4 on the cell surface (Abdulkhalek et al. 2011) . Consistent with negative regulation by sialic acid residues of the hyaluronic acid receptor function of CD44 on CD4+ T-cells (Katoh et al. 1999) , acute asthmatic reactions, including Th2-mediated airway inflammation and airway hyperresponsiveness, are dependent on NEU1 enzymatic activity (Katoh et al. 2010 ). In the process of recruitment of leukocytes to inflammatory sites, an endogenous sialidase promotes the binding of β2 integrins (CD11b/CD18) on polymorphonuclear leukocytes with Intercellular Adhesion Molecule 1 (ICAM-1) on endothelial cells by the removal of sialyl residues from the activation epitopes on the adhesion molecules, resulting in the enhanced recruitment of leukocytes to inflammatory sites (Feng et al. 2011) . The sialidase involved in this event has been suggested to be NEU1 by its colocalization with CD18 and PMA-stimulated sialidase activity toward 4MU-NeuAc on the cell surface on confocal microscopy, although the possibility that it might be NEU3 also remains because of the use of a substrate inappropriate for the enzyme.
The elastin-binding protein (EBP), identical to a spliced variant of β-galactosidase, forms a cell surface-targeted complex with PPCA and NEU1 (Hinek et al. 2006 ). The T Miyagi and K Yamaguchi carboxypeptidase activity of PPCA is required for EBP complex formation, participating in regulation of blood pressure as an endothelin-1 inactivating enzyme (Seyrantepe, Hinek et al. 2008 ), although it is thought to be unnecessary for complex formation with NEU1 and β-galactosidase in lysosomes. Furthermore, NEU1 inhibits the proliferation of aortic smooth muscle cells and fibroblasts by desialylation of both PDGF and IGF-1 receptors and also regulates the proliferative responses of skeletal myoblasts to insulin by desialylation of insulin and IGF-1 receptors in a different manner, depending on insulin concentration (Arabkhari et al. 2010 ). NEU1 has further been reported to participate in NGF-induced Trk tyrosine kinase receptor activation and cellular signaling probably by complex formation with matrix metalloproteinase-9 at cell surfaces ). These observations suggest that, in addition to lysosomal catabolism, NEU1 regulates various important cellular phenomena through desialylation of surface molecules, presumably after mobilization to the cell surface.
Several cancers show a tendency for decreased NEU1 expression. Interestingly, there is a good inverse relationship with metastatic ability, also evident with the NEU1 reduction in rat 3Y1 fibroblasts after src-transformation. Furthermore, v-fos transfer to the transformed cells induced an even more severe decrease in sialidase activity and acquired higher lung metastatic potential (Miyagi et al. 1994 ). In mouse adenocarcinoma colon 26 cells, compared with low metastatic NL4 and NL44 cell lines, highly metastatic NL17 and NL22 cells exhibit lower expression of NEU1 sialidase, accompanied by higher levels of sialyl Le x and GM3 (Sawada et al. 2002) . As expected, introduction of Neu1 sialidase into Bl6 melanoma cells resulted in suppression of experimental pulmonary metastasis and tumor progression, with a reduction in anchorage-independent growth and increased sensitivity to apoptosis (Kato et al. 2001) . Overexpression of the human NEU1 with PPCA gene brought about similar alterations of human cancer cells to those observed in murine cells, such as suppressed cell migration and invasion in the colon adenocarcinoma HT-29 case, whereas its knockdown resulted in the opposite. When NEU1-overexpressing cells were injected trans-splenically into mice, the in vivo liver metastatic potential was reduced significantly. One of the target molecules of NEU1 was found to be integrin β4, which undergoes desialylation and decreased phosphorylation followed by attenuation of the focal adhesion kinase and extracellular signal regulated kinase 1/2 (ERK1/2) pathway and down-regulation of matrix metalloproteinase-7 (Uemura et al. 2009 ), as illustrated in Figure 3 (right panel). A microRNA, miR-125b, has been found to promote growth of prostate cancers in both intact and castrated male nude mice by down-regulating pro-apoptotic and tumor suppressor genes (Shi et al. 2011) . Interestingly, miR-125b targets eight transcripts including NEU1 as metastatic suppressor, consistent with the NEU1 effects described above.
Sialidase NEU2
Cytosolic sialidase NEU2 was the first example of a mammalian sialidase for which cDNA cloning was achieved based on the peptide sequence of the sialidase protein purified from rat skeletal muscle (Miyagi et al. 1993 ). Homologs were subsequently cloned from cDNA libraries of Chinese hamster ovary (CHO; Ferrari et al. 1994) , mouse brain (Fronda et al. 1999; Hasegawa et al. 2000) and mouse thymus (Kotani et al. 2001) and from a genomic library of human skeletal muscle (Monti et al. 1999) , all showing high amino acid identity (70-98%) to the rat gene. The identified coding region of the human gene is subdivided into two exons ( Figure 1A ), mapping to 2q 37.1. Although detailed information is lacking, a 4-kb transcript for the human NEU2 gene has been detected in muscle by northern blotting (Monti et al. 1999) . Cytosolic localization of NEU2 has been evidenced was determined by biochemical subcellular fractionation (Miyagi and Tsuiki 1985) and by immunostaining of the cells with anti-NEU2 antibody . In general, the occurrence of glycoconjugates in the cytosol may be considered as an unusual event, probably because of its lack of involvement in major glycosylation pathways. However, there has been a report of cytosolic presence of glycoproteins, oligosaccharides and gangliosides and also of glycosidases and lectins involved in metabolism and recognition of the glycan molecules (Funakoshi and Suzuki 2009 ). There are many examples of delivery of misfolded glycoproteins from the endoplasmic reticulum (ER) Fig. 3 . Opposite roles of two human sialidases, NEU1 and NEU3, in integrin β4-mediated signaling on laminin-5 in colon cancer cells. NEU1 inhibits interim β4 signaling probably at cell surfaces through the sialic acid removal of the carbohydrate portion of integrin followed by decreased tyrosine phosphorylation and subsequent attenuation of signaling through the FAK and ERK1/2 pathway (Uemura et al. 2009 ). On the other hand, the signaling activation results from the NEU3 enhancement of phosphorylation of integrin with the recruitment of Shc and Grb-2 through ganglioside modulation (Kato et al. 2006) . The data suggest that NEU1 and NEU3 act on the same target, integrin in this case, in an opposite manner by a different mechanism: probably by sialic acid removal from the carbohydrate portion and by ganglioside modulation, respectively. The long arrow indicates the possible mobilization of NEU1 from the lysosomes to the cell surface, although the molecular mechanism remains to be solved.
Cellular functions of mammalian sialidases
into the cytosol via the ER-associated degradation (ERAD) pathway, of free oligosaccharides deglycosylated from ERAD substrate glycoproteins by the cytosolic peptide:N-glycanase and of gangliosides binding to vimentin or other intermediate filaments. The available information suggests that NEU2 plays physiologically significant roles in the cytosol. In this context, it is of interest that the cytosolic NEU2 or NEU1 leaked from lysosomes possibly participates in the degradation of complex-type N-glycans in the cytosol of MKN7 and MKN45 stomach cancer cells, in which accumulation of free complex-type N-glycans occurs (Ishizuka et al. 2008) . Detection of disialobiantennay oligosaccharides as well as those of high mannose type in the cytosolic fractions of the mouse liver (Ohashi et al. 1999 ) may point to NEU2 activity as an enzyme responsible for N-glycan degradation, in line with the cytosolic abundance of this enzyme in the rat tissues.
Unlike NEU1 sialidase, NEU2 is able to hydrolyze a wide range of glycoproteins, oligosaccharides and gangliosides at near neutral pH. It participates in muscle cell and neuronal differentiation, and the rat Neu2 gene is highly expressed in rat skeletal muscle. The rat gene contains two E-box pairs, known to be consensus binding sites for muscle-specific transcription factors, in the 5′-flanking enhancer/promoter region. This region exhibits transcriptional activity in rat L6 (Sato and Miyagi 1995) and murine C2C12 (Fanzani et al. 2003) myogenic cells, and activity as well as the mRNA level is increased during myotube formation, indicating that the enzyme plays a critical role in muscle cell differentiation. In this context, it is interesting that the SJL mouse, a model for human dysferlinopathy, shows down-regulation of Neu2 gene, this probably being involved in impaired muscle regeneration (Suzuki et al. 2005) . Further support for the sialidase participating in myogenic functions is provided by defective myogenic differentiation displayed in human rhabdomyosarcoma cells, accompanying suppression of NEU2 expression (Stoppani et al. 2009 ), although it is unclear whether the down-regulation is a consequence of tumorigenesis, and up-regulation abrogates this effects. In PC12 cells, murine NEU2 may participate in neuronal differentiation through nerve-growth factor (NGF)-induced transcriptional activation (Fanzani et al. 2004) .
Several studies of whether NEU2 up-regulation affects cancer cell behavior have been conducted. Introduction of rat Neu2 gene into a B16-BL6 mouse melanoma cell line, highly invasive and metastatic, also caused a marked decrease in pulmonary metastasis, with a decrease in the ganglioside GM3 and an increase in lactosylceramide (Tokuyama et al. 1997) . When the same gene was transfected into highly metastatic mouse colon 26 adenocarcinoma cells (Sawada et al. 2002) , intravenous injection into syngeneic mice resulted in marked reduction in lung metastasis, invasion and cell motility, with a concomitant decrease in sialyl Le x and GM3 levels, in line with spontaneously low metastatic sublines having a relatively high level of the endogenous sialidase. Treatment of the cells with antibodies against sialyl Le x and GM3 affected cell adhesion and/or cell motility, providing direct evidence that the desialylation of these molecules, as targets of sialidase, is involved in the suppression of metastasis. The highly metastatic cells exhibited rather decreased sialic acid contents, both total and cell surface, when compared with the low metastatic cells, consistent with the increased sialidase activity. The results together indicate that the sialidase level may be a determining factor for metastatic ability independent of the cell type and irrespective of the sialic acid content. Another line of the experiments with NEU2 in cancer cells showed significant effects on cell growth and apoptosis. Transfection of the CHO Neu2 gene into the A431 human epidermoid carcinoma cell line reduced GM3 levels and enhanced cell growth and tyrosine autophosphorylation of epidermal growth factor receptors (EGFRs) at low EGF concentration (Meuillet et al. 1999) . Introduction of the human NEU2 gene into leukemic K562 cells induced a marked decrease in anti-apoptotic factors Bcl-XL and Bcl-2, resulting in increased sensitivity to apoptotic stimuli (Tringali et al. 2007 ). NEU2 overexpression in the cells reduced gene expression and activity of Bcr-Abl, together with a decrease in Bcr-Abl-dependent Src and Lyn kinase activity probably brought about by desialylation of some cytosolic glycoproteins. As mentioned earlier, it is uncertain how NEU2 actually functions in human tissues and cells, because of its extremely low expression. The biological and phylogenic significance of marked decrease in NEU2 expression in the human tissues thus remains to be elucidated.
Sialidase NEU3
The NEU3 cDNA was first cloned from a bovine brain library , based on peptide sequence information for the purified enzyme protein, as well as from a human skeletal muscle cDNA library ) and the human genome database (Monti et al. 2000) . Primary sequences covering the entire coding region of the corresponding human, mouse and rat genes display 80% overall identity with the bovine gene. Human NEU3 gene comprises four exons encompassing over 22 kb ( Figure 1A ) and maps to 11q13.5. Northern blot analysis has shown two transcripts of different length (2.5 and 7 kb; Wada et al. 1999) , which may be the result of utilization of different poly (A) additional signals located in exon 4. Expression of the gene is relatively high in human brain and muscle and in mouse heart, although all tissues examined exhibit substantial levels. A recent study ) on NEU3 gene expression provided evidence of diverse regulation by Sp1/Sp3 transcription factors binding to alternative promoters, the latter accounting for multiple modulation. Multiple transcriptional start sites have been identified in two clusters, one preferentially utilized in various tissues as well as in cell lines including NB-1 (neuroblastoma) and A172 (glioblastoma), and the other preferentially utilized only in the brain. Recent annotation of TSSs in the human genome indicated the existence of alternative promoters in many tissue-specific genes and genes encoding molecules involved in signal transduction (Kimura et al. 2006) . Although the physiological control of alternative promoters remains to be elucidated, they might allow genes to be finely regulated at the transcriptional and post-transcriptional levels. Luciferase reporter assays of wild type and mutated promoter regions of the NEU3 gene have indicated that Sp1-binding motifs, a CAAT box and a CAAC motif are T Miyagi and K Yamaguchi important for promoter activity in many cell lines. Transcription factors Sp1 and Sp3 bind to the assigned Sp1-binding motif of the NEU3 gene and seem to play a role in selection of the two clusters of transcriptional start site.
The bovine and human enzymes almost specifically hydrolyze gangliosides, whereas the murine enzyme acts on oligosaccharides, 4MU-NeuAc and glycoproteins to a certain extent. Gangliosides GD3, GM3, GD1a and even GD1b, but not GM1 and GM2, are good substrates in the presence of Triton X-100. Interestingly, the mouse NEU3, but not NEU2, seems to remove even the stable sialic acid of GM1 and GM2 in the presence of GM2 activator protein (Li et al. 2001) , supporting the presence of the GA2 (asialo GM2) pathway for the GM2 catabolism in mouse. The human enzyme acts on GM3 but hardly impacts on sialyllactose, suggesting that a ceramide moiety might be critical for catalysis. However, quite recently, it was proposed that only a hydrophobic aglycon is required for the strict ganglioside preference (Sandbhor et al. 2011) , not ceramide itself. Site-directed mutagenesis studies on NEU3 have generated evidence of residues involved in the recognition and hydrolysis of ganglioside substrates. In particular, recent studies using the more precise information available on the NEU2 3D structure (Chavas et al. 2005) have confirmed that mutations of residues expected to interact with the N-5 acetyl group (A160, M87, I105) and the glycerol side chain (E113A, Y179F, Y181F) of sialic acid result in a great decrease in enzyme activity, thus suggesting direct relevance in the recognition of sialic acid by the active site . Unlike the bovine and murine enzymes, with only one activity peak at a pH near 4.6, the human enzyme, NEU3, shows two peaks at pH 4.5-4.8 and pH 6.0-6.5. Recently, through synthesis of a series of C9-triazole derivatives of DANA and evaluation of their NEU3 inhibitory potency, some derivatives were found to possess comparative potency to DANA with 4MU-NeuAc as substrates ). However, their selectivity could not be determined, because of the lack of observations on other sialidase forms. The major subcellular localization of the bovine and murine sialidases proved to be plasma membranes on Percoll density gradient centrifugation of cell homogenates and immunofluorescence staining. The human NEU3, however, is not always detected on cell surfaces but may also exist in other cellular membrane components and can mobilize to membrane ruffles together with Rac-1 in response to growth stimuli such as EGF, enhancing cell movement . A report on membrane topology suggested the enzyme to be localized partially on the cell surface as a peripheral membrane protein and also in endosomal structures (Zanchetti et al. 2007 ). With administration of the radiolabeled ganglioside GD1a to murine Neu3-transfected cells, NEU3 was shown to hydrolyze ganglioside substrates in intact living cells at a neutral pH, with involvement of cell-to-cell interactions .
Because of its unique substrate specificity and association with the plasma membrane, NEU3 is presumed to be a potentially important molecule for various cell surface events. Murine NEU3 can regulate cell apoptosis in human fibroblasts by producing ceramides from GM3 in plasma membranes through further degradation of the sugar unit (Valaperta et al. 2006) . Previous biochemical studies suggested the cell surface presence and its essential role of ganglioside sialidase in the processes of proliferation control and differentiation in neuroblastoma cells (Kopitz et al. 1994 (Kopitz et al. , 1998 , and later using a cDNA clone, NEU3 was indeed confirmed to positively participate in neurite formation in mice (Hasegawa et al. 2000) and in human neuroblastoma cells (Proshin et al. 2002) , and in regulation and regeneration of rat hippocampus neurons (Rodriguez et al. 2001; Da Silva et al. 2005) . Consistent with these results, NEU3 sialidase activity remained high with differentiation and aging in culture of rat cerebellar granule cells, accompanied by increased β-galactosidase and β-glucosidase activity and paralleling ceramide levels in plasma membranes (Aureli et al. 2010 ). An involvement of NEU3 in skeletal muscle differentiation and apoptosis has been shown by gene knockdown in murine C2C12 cells causing inhibition of myotube formation and sensitization to apoptotic stimuli, with accumulation of GM3 subsequent to inhibition of epidermal growth factor receptor actions (Anastasia et al. 2008) . NEU3 gene expression leads to inhibition of TNF-α-induced matrix metalloproteinase-9 expression in vascular smooth muscle cells by decreasing the promoter activity in response to TNF-α, suggesting contributions to plaque instability in atherosclerosis as a physiological modulator of smooth muscle cell responses (Moon et al. 2007) . NEU3 is located in rafts of neuroblastoma cells (Kalka et al. 2001 ) and in caveolae of HeLa cells (Wang, Yamaguchi et al. 2002) , closely associated with caveolin-1, probably through the caveolin-binding region. In caveolae, NEU3 has been proposed to control platelet-derived growth factor (PDGF)-induced Src mitogenic signaling and DNA synthesis by modification of GM1 levels at cell surfaces. A member of the transmembrane adaptor protein family, PAG, induces NEU3 sialidase activity and GM1 accumulation, subsequently excluding PDGF receptors from caveolae and inhibiting Src mitogenic signaling, although it remains unclear how PAG ( protein associated with glycosphingolipid-enriched microdomains) affects NEU3 activity (Veracini et al. 2008) . Depletion of ganglioside GM3 by NEU3 causes increased EGFR phosphorylation and inhibition of the EGF-induced tyrosine phosphorylation of caveolin-1, leading to the activation of EGFR signaling by retention of caveolin-1 in caveolae (Wang, Sun et al. 2002) . Like NEU1 as described earlier, human NEU3 has been found to contribute to the development of adaptive immune responses. The NEU3 was up-regulated together with NEU1 during differentiation of monocytes into dendritic cells. Lipopolysaccharide (LPS)-induced production of cytokines, including IL-6, IL-12p40 and tumor necrosis factor, TNF-α in mature dendritic cells was reduced by zanamivir, an efficient inhibitor for NEU3, and also by DANA, an inhibitor of NEU1 and NEU3, in the cells from Neu1(−/−) and wild-type mice, suggesting an involvement of NEU3 in the cytokine production by desialylation of specific cell surface glycoconjugates (Stamatos et al. 2010) .
Up-regulation of NEU3 is observed in various neoplasms including colon, renal, ovarian and prostate cancers, although the down-regulation has been noted in acute lymphoblastic leukemia linked to disease progression (Mandal et al. 2010) . In human colon cancers, NEU3 mRNA levels were found to Cellular functions of mammalian sialidases be increased 3-100-fold when compared with adjacent nontumor mucosa, and in situ hybridization analysis with antisense probes demonstrated positive signals to be localized to carcinoma cells, not to surrounding stromal cells (Kakugawa et al. 2002;  Figure 4A ). During sodium butyrate-induced apoptosis, human colon cancer cells show the down-regulation of NEU3 expression, in contrast to the up-regulation of NEU1. Transfection of an NEU3 gene into cancer cells was found to inhibit sodium butyrate-induced apoptosis, accompanied by increased Bcl-2 protein and decreased caspase expression. Colon cancer tissues exhibit marked accumulation of lactosylceramide, a possible NEU3 product, and addition of this glycolipid to cultures reduced apoptotic cells during sodium butyrate treatment. Furthermore, in colon cancer cells, NEU3 differentially regulated cell proliferation through integrin-mediated signaling depending on the extracellular matrix (Kato et al. 2006) , causing increased adhesion to laminins and consequent cell division, but rather decrease in cell adhesion to fibronectin and collagen I and IV. Triggered by laminins, NEU3 markedly enhanced tyrosine phosphorylation of integrin β4, with recruitment of Shc and Grb-2, stimulating the phosphorylation of focal adhesion kinase and ERK1/2 (Figure 3, left panel) . Interestingly, in contrast to NEU3, NEU1 attenuated this integrin-mediated signaling by reducing the phosphorylation, as illustrated earlier in the same figure. NEU3 mRNA levels are also reported to be significantly increased in renal cell carcinomas (Ueno et al. 2006) , correlating with elevation of IL-6, a pleiotropic cytokine. NEU3 activation by IL-6 directs IL-6-mediated signaling via the PI3K/ Akt cascade in a positive feedback manner and thus may contribute to a malignant phenotype, including suppression of apoptosis and promotion of cell motility in RCCs. Up-regulation of NEU3 was also detected in prostate cancer ( Figure 4B) , showing a significant correlation with malignancy as assessed by the Gleason score (Kawamura et al. 2012) . In androgen-sensitive LNCaP cells, forced overexpression of NEU3 significantly induced progression-related transcription factor EGR-1, androgen receptors and prostate specific antigen, PSA, both with and without androgen, the cells becoming hormone sensitive. This NEU3-mediated induction was abrogated by inhibitors of phosphatidylinositol 3 (PI-3) kinase and mitogen-activated protein kinase (MAPK), in line with increased phosphorylation of AKT and ERK1/2 in NEU3-overexpressing cells. NEU3 small interfering RNA (siRNA) introduction moreover caused a reduction in the cell growth of androgen-independent PC-3 cells in culture and of transplanted tumors in nude mice. These data strongly suggest that NEU3 regulates the progression of prostate cancer through androgen receptor signaling. Another report on NEU3 effect in prostate cancer PC-3 cells demonstrated that NEU3 Fig. 4 . Up-regulation of sialidase NEU3 in colon and prostate cancers. (A) NEU3 mRNA levels in colon cancer tissues and non-cancerous mucosa (closed and open columns, respectively; upper panel) and in situ hybridization of NEU3 in colon cancer tissues (lower panel) (Kakugawa et al. 2002) . (B) NEU3 mRNA levels in prostate cancer and non-cancerous tissues (upper panel). Note the significant correlation with malignancy as assessed with reference to the Gleason score (lower panel) (Kawamura et al. 2012 ).
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knockdown significantly decreased invasion and migration accompanied with decreased expressions of the matrix metalloproteinases MMP-2 and MMP-9, and mice injected with PC-3 cell tumors developed fewer bone metastases by treatment with the NEU3 siRNA than control (Li et al. 2011) .
To define further the molecular mechanisms of NEU3 influence and its possible targets, the encoding gene has been silenced by siRNA or overexpressed in various human cancer cells ). Silencing caused apoptosis without specific stimuli, accompanied by decreased Bcl-xL and increased mda7 and GM3 synthase mRNA levels in HeLa cells, whereas overexpression resulted in the opposite effects. Human colon and breast carcinoma cell lines, HT-29 and MCF-7 cells, appeared to be similarly affected by treatment with the NEU3 siRNA, but interestingly non-cancerous human WI-38 and NHDF fibroblasts and NHEK keratinocytes showed no significant changes. NEU3 siRNA was found to inhibit and NEU3 overexpression to stimulate Ras activation with consequent influence on ERK and Akt. Ras activation by NEU3 was largely abrogated by PP2 (an src inhibitor) or AG1478 (an EGFR inhibitor), and in fact, siRNA introduction reduced the phosphorylation of EGFR, whereas overexpression promoted its phosphorylation in response to EGF. The fact that NEU3 co-immunoprecipitated with EGFR, and EGF stimulation yielded a higher amount of immunoprecipitable NEU3 further indicate that it suppresses apoptosis of cancer cells by promoting EGFR phosphorylation, probably through its association with EGFRs and consequent activation of Ras cascades, especially via the Ras/ERK pathway.
To summarize the significance of NEU3 up-regulation in cancer, the sialidase activates molecules including EGFR, FAK, ILK, Shc and integrin β4, often up-regulated in carcinogenesis, and may thus cause accelerated development of a malignant phenotype. Up-regulation of NEU3 has also been established to have importance for the promotion stage of colorectal carcinogenesis in vivo, from experiments using NEU3 transgenic mice ). Thus NEU3 was found to increase azoxymethane-induced aberrant crypt foci formation in colon mucosa by suppression of apoptosis, possibly via the activation of EGF signaling. Taking into account all of the evidence, NEU3 is certainly involved in the regulation of transmenbrane signaling at the cell surface through both modulation of gangliosides as the result of enzyme reactions and by interaction with other signal molecules, including caveolin-1, Rac-1, integrin β4, Grb-2 and EGFR .
Surprisingly, NEU3 transgenic mice develop impaired insulin signaling and insulin-resistant diabetes mellitus by 18-22 weeks (Sasaki et al. 2003) , associated with hyperinsulinemia, islet hyperplasia and increase in the β-cell mass. When compared with the wild type, insulin-stimulated phosphorylation of the insulin receptor and insulin receptor substrate I is significantly reduced, and activities of PI-3 kinase and glycogen synthase are also decreased. In muscle extracts, an association of tyrosine-phosphorylated NEU3 with Grb2 was observed in response to insulin, together with the accumulation of GM1 and GM2. The apparent involvement of NEU3 in both cancer progression and development of diabetes supports the conclusion that these diseases might be closely related to each other in pathogenesis, in line with recent epidemiological reports of higher cancer risk in diabetic patients than in controls.
As described earlier, it has been documented that NEU3 expression is diversely regulated by Sp1/Sp3 transcription factors binding to alternative promoters. Such transcriptional control might also account for the up-regulation of NEU3 in cancer, because Sp1 and Sp3 were initially considered as constitutive activators of housekeeping genes but have recently been documented to play critical roles in regulating the transcription of genes involved in cell growth control and tumorigenesis (Wierstra 2008) . In fact, the expression of NEU3 exhibited good correlations with those of Sp1 or Sp3 in cancer, implying a promoting role in NEU3 gene transcription.
Sialidase NEU4
The mouse and human NEU4 genes were initially identified by database searches (Comelli et al. 2003; Monti et al. 2004; Seyrantepe et al. 2004; Yamaguchi et al. 2005) . In the human case, it is composed of four exons encompassing over 6 kb ( Figure 1A ) and has been mapped to 2q37.3. Two forms of NEU4 are suggested, long and short, the long form having an additional 12-amino acid sequence at the N-terminus ( Figure 1B ), which can act as a mitochondrial targeting signal (Yamaguchi et al. 2005) . Transcripts with different 5′ exons encode the two forms, which are generated by alternative splicing. The isoforms are differentially expressed in a tissuespecific manner. The brain, muscle and kidney contain both, whereas the liver and colon possess predominantly the short form, as assessed by RT-PCR. The mouse NEU4 also present as two isoforms derived from alternating splicing, designated NEU4a and NEU4b (Shiozaki, Koseki et al. 2009 ). Mouse NEU4a has an additional 23 amino acid stretch at N-terminus and exhibits lower enzymatic activity than NEU4b ( Figure 1B) . The mouse Neu4 gene is expressed dominantly in the brain (Comelli et al. 2003) and is only found at very low levels in other tissues. The expression level of the mouse gene increases 3-14 days after birth (Shiozaki, Koseki et al. 2009 ) suggesting a role for brain development, presumably through digestion of polysialic acids on surfaces of neuronal cells.
With regard to the subcellular localization of the human NEU4, two different descriptions have been reported on the basis of gene transfection studies: one demonstrated targeting to the lysosomal lumen (Seyrantepe et al. 2004) , and the other to mitochondria for the long form and endoplastic reticulum for the short form (Yamaguchi et al. 2005; Bigi et al. 2010 ). The isoforms possess broad substrate specificity, including activity toward mucin. Expression of human NEU4 gene in cells of sialidosis patient results in the clearance of storage materials from lysosomes and thus NEU4 may be useful for novel therapeutic purposes (Seyrantepe et al. 2004) . Although NEU4-deficient mice lack gross morphological abnormalities, their ganglioside patterns featured increased GD1a and decreased GM1 in the brain (Seyrantepe, Landry et al. 2008) . Furthermore, mice with a double deficiency of NEU4 and β-hexosaminidase A suffer epileptic seizures and rapid Cellular functions of mammalian sialidases neuronal loss accompanied with GM2 accumulation. Unlike human Tay-Sachs disease, hexosaminidase A-deficient mice have been characterized as remaining asymptomatic for over 1 year, GM2 catabolism being expected. In this context, results for double-deficient mice indicate that NEU4 is a sialidase involved in the mouse model of Tay-Sacks disease, possibly acting as a ganglioside-metabolizing sialidase in vivo (Seyrantepe, Lema et al. 2010) . A recent report suggested that NEU4 is activated by thymoquinone from the Nigella sativa plant in various cells including macrophages and that the induced NEU4 activity is related to the activation of NFkB and proinflammatory cytokine production .
Human NEU4 may be involved in neuronal cell apoptosis, based on the observation that a long form including the mitochondrial-targeting signal exists predominantly in the brain and probably impacts on the level of GD3 in neuroblastoma cells (Hasegawa et al. 2007) , consistent with the proposal that GD3 could act as an apoptosis-inducing ganglioside (Malisan and Testi 2002) . Although localization of a sialidase in mitochondria is unexpected, it is feasible that NEU4 might degrade GD3 in mitochondria considering the targeting of GD3 from rafts to mitochondria in apoptogenic events, contributing to mitochondrial alterations leading to cell death (Sorice et al. 2009 ). Furthermore, in a mouse model of human GM1-gangliosidosis, gangliosides GM1 have been observed to accumulate in the glycosphingolipid-enriched microdomain fractions of mitochondria-associated ER membranes, the sites of ER/mitochondria juxtaposition that control Ca 2+ flux between these organelles in neuronal cells (Sano et al. 2009 ). The presence of small amounts of GM1 even in the wild-type case suggests that gangliosides at the site of mitochondriaassociated ER membranes act as apoptosis effectors by altering Ca 2+ dynamics. Thus, NEU4 may also regulate Ca
2+
-dependent mitochondrial apoptosis through ganglioside hydrolysis.
In contrasting to NEU3, murine NEU4 appears to negatively regulate neurite formation (Shiozaki, Koseki et al. 2009 ), being down-regulated in Neuro2a cells during retinoic acidinduced differentiation. Furthermore, Neu4 overexpression resulted in suppression of neurite formation and its knockdown in acceleration. As illustrated in Figure 5 , NEU3 and NEU4 thus function in neurite formation of the same cells in opposing directions. The two enzymes both can act on gangliosides, but the endogenous substrate for NEU4 in this case seem to be 95 kDa of glycoprotein. However, definite target molecules have yet to be identified. NEU4 mRNA levels have been reported to be markedly decrease in human colon cancer (Yamanami et al. 2007) , in clear contrast to the NEU3 case. Levels were not significantly correlated with the histological differentiation or the pathological stage, but the T/NT (tumor to non-tumor expression ratio) value remained significant at P = 0.025 with venous invasion between v0 (n = 28) and v1-3 (n = 13). In cultured human colon cancer cells, the enzyme was found to be up-regulated in early stages of apoptosis induced by either the death ligand TRAIL or serum-depletion. Transfection of NEU4 into DLD-1 and HT-15 colon adenocarcinoma cells resulted in acceleration of apoptosis and decreased invasiveness and cellular motility. siRNA-mediated NEU4 targeting, on the other hand, caused a significant inhibition of apoptosis and promotion of cellular invasiveness and motility. To elucidate the significance of NEU4 down-regulation in colon cancer, sialyl-Lewis antigens, sialyl-Le a and sialyl-Le x , as endogenous substrates for the sialidase were investigated (Shiozaki et al. 2011) , because they are utilized as tumor markers, and their increase in cancer is associated with tumor progression. NEU4 was found to hydrolyze the antigens in vitro and decrease cell surface levels much more effectively than other sialidases. Western blot, thin-layer chromatography and metabolic inhibition studies of desialylation products revealed NEU4 to preferentially catalyze sialyl-Lewis antigens expressed on O-glycans. Cell adhesion to and motility and growth on E-selectin were significantly reduced by NEU4. Furthermore, E-selectin stimulation of colon cancer cells enhanced cell motility through the activation of the p38/ Hsp27/actin reorganization pathway, whereas NEU4 attenuated the signaling. It is interesting to note in this context that the sialidase does not change the level of a normal glycan, disialyl-Le a , generally expressed in non-malignant epithelial cells. Although it has been proposed that glycosyltransferases are responsible for synthesis of these antigens, expression levels of the encoding genes have not always been found to correlate with sialyl-Lewis antigen contents, with even contradictory expression noted. It is feasible that desialylation by NEU4 may occur specifically with cancer related sialyl-Lewis antigens and thus maintenance of the normal glycan level can be achieved in colon mucosa highly expressing NEU4.
Further evidence for sialidase involvement in cellular functions
Intriguing descriptions of sialidase participation in other important cellular functions have appeared, although it is not always clear to which type of sialidase activities can be attributed. The secreted form of Klotho protein, loss of which results in accelerated aging characterized by atherosclerosis, osteoporosis and skin atrophy (Kuro-o 2009), possesses putative sialidase activity preferentially acting on α2-6 sialyl linkage sugar chains of cell surface glycoproteins (Cha et al. 2008) . The klotho gene encodes a single-pass transmembrane protein, and the extracellular domain is clipped to generate a secreted form of Klotho protein that is detectable as a single peptide in the blood, urine and cerebrospinal fluid. The secreted Klotho protein is known to inhibit insulin/IGF-1 signaling. Differing from the secreted form, the transmembrane Klotho protein functions as a co-receptor for fibroblast growth factor (FGF)23 when it forms a complex with FGF receptors on cell surfaces. In melanoma cells (Camilli et al. 2010) , where the expression of Wnt5A and Klotho are inversely correlated, recombinant Klotho has been shown to decrease Wnt5A signaling, coincident with increased sialidase activity, leading to suppression of melanoma cell motility through decrease in filamin cleavage and syndecan expression. These phenomena were blocked by a sialidase inhibitor, suggesting that Klotho-mediated sialidase activity may regulate aging and tumor invasion. However, in the primary sequence of Klotho gene, there is no Asp box or F(Y)RIP sequence conserved in mammalian as well as microbial sialidases. In addition, it has T Miyagi and K Yamaguchi been also described that recombinant Klotho protein lacks β-glucosidaselike enzymatic activity, in spite of the secreted Klotho protein having homology to family 1 glycosidases including β-glucosidase. The secreted Klotho protein, therefore, presumably participates in cell events, including insulin/IGF-1 signaling, via activation of one of the four sialidase types.
The existence of sialidase activity in myeloma patient sera has been reported, apparently tightly associated with immunoglobulin IgG fractions as catalytically active antibodies (named abzymes) typically found in patients with autoimmune disorders and also cancer patients, but not in normal healthy donors. An IgG possessing sialidase-like activity has been shown to act on 4MU-NeuAc as a substrate and to increase PNA-induced agglutination of human erythrocytes (Bilyy et al. 2011) . It again remains uncertain whether the sialidase activity is due to any of the four established types or others such as microbial species, but the possible biological significance is of great interest.
In the nervous system, infusion of exogenous sialidase to injury sites has been observed to enhance spinal axon outgrowth and regeneration and promote recovery in a rat model of brachial plexus avulsion and after spinal cord contusive injury. The adult injured central nervous system is generally incapable of axon regeneration, partly due to the accumulation of axon regeneration inhibitors including myelin-associated glycoprotein, NogoA and oligodendrocyte-myelin glycoprotein on residual myelin, and chondroitin sulfate proteoglycans on astrocytes, and some of these inhibitors bind to specific receptors on the axon growth cone to block outgrowth. In the rat reports of recovery, Clostridium perfringens sialidase (Yang et al. 2006 ) and recombinant Vibrio cholerae sialidase Fig. 5 . Opposite roles of two murine sialidases, NEU3 and NEU4, in neurite formation during retinoic acid-induced neuronal differentiation in Neuro2a cells. NEU3 is up-regulated during neuronal differentiation and accelerates neurite formation (Hasegawa et al. 2000) , whereas NEU4 attenuates retinoic acid-induced differentiation (Shiozaki, Koseki et al. 2009 ). Cells were cultured in medium containing 20 μM retinoic acid, and cells bearing neurites at least 2.0-fold the length of the soma diameter were counted at the times indicated. Photographs of Neuro2a cells treated with retinoic acid for 48 h at ×100 magnification.
Cellular functions of mammalian sialidases (Mountney et al. 2010) were used for experimental therapeutic purposes, and the enhanced motor and autonomic functional recovery, probably resulted from destruction of the glycanbinding determinant of myelin-associated glycoprotein. The results suggest sialidase might be a candidate therapeutic agent for spinal cord injury. If a sialidase of human origin, probably the most appropriate sialidase NEU3 as described earlier, could be applied, the potential would be enormous.
Future perspectives
With recent progress in elucidation of the significance and molecular basis of pathophysiological desialylation, evidence has accumulated that mammalian sialidases play important roles in various cellular functions. However, these remained largely unexplored, partly due to low expression levels and instability of endogenous sialidases relative to other proteins. For example, even the physiological subcellular localization of all except the most highly expressed NEU1 form remains unclear. Although transfection studies with respective cDNAs have provided evidence of subcellular sites, overexpression of recombinant proteins might often result in artificial patterns. The molecular basis of the biologically and phylogenically marked decrease in NEU2 expression in humans should also be elucidated, perhaps in comparison with murine tissues which exhibit expression levels very similar to those of NEU3 and NEU4. Regarding functional aspects, each sialidase seems to play a unique role depending on its particular enzyme properties including substrate specificity. In addition to lysosomal catabolism, NEU1 is involved in immune functions at cell surfaces, as expected by the gene locus in MHC, whereas NEU3 and NEU4 regulate neuronal differentiation in opposite ways. It is also interesting to note that the two sialidases NEU1 and NEU3 appear to have unique functions opposing each other, through preferentially desialylating glycoproteins and gangliosides, respectively, even if targeting the same molecule in the same cells, as illustrated in Figure 3 . Numerous studies have disclosed the molecular basis of pathological desialylation in sialidosis caused by NEU1 deficiency, and abnormal up-regulation of NEU3 has been demonstrated to drive progression in various carcinomas. In particular, it is of importance to investigate the detailed molecular mechanisms of NEU1 involvement in immune responses, which might conceivably lead to elucidation of infectious and autoimmune disease processes. Discovery of specific tools for NEU3 down-regulation could throw light on development of novel cures for cancer. With regard to antiinfluenza drugs such as Tamiflu, it might be advisable to examine newly discovered drug targeting viral sialidases for their effects on human isoforms in order to minimize side effects in patients. Further investigation of mammalian sialidases should clarify the molecular basis of pathological phenomena resulting from aberrant sialylation and provide clues to controlling the degree of sialylation of functional molecules. Thus, for therapeutic purposes, modulation of sialidase expression might be effectively achieved by appropriate use of recombinant sialidases for up-regulation, or specific inhibitors, antibodies and siRNAs for down-regulation.
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